Wall Street analysts forecast that ContraFect Corp (NASDAQ:CFRX) will post earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for ContraFect’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). ContraFect posted earnings of ($0.08) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 12.5%. The firm is expected to announce its next quarterly earnings results on Thursday, March 12th.
On average, analysts expect that ContraFect will report full-year earnings of ($0.10) per share for the current fiscal year, with EPS estimates ranging from ($0.14) to ($0.03). For the next financial year, analysts forecast that the firm will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.51) to ($0.25). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for ContraFect.
ContraFect (NASDAQ:CFRX) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01.
Separately, Maxim Group reiterated a “buy” rating and set a $2.00 target price on shares of ContraFect in a research report on Friday, October 4th.
Shares of CFRX traded down $0.01 during mid-day trading on Friday, reaching $0.35. The stock had a trading volume of 200 shares, compared to its average volume of 266,063. The business has a fifty day moving average of $0.32 and a 200 day moving average of $0.40. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.68 and a current ratio of 1.68. The firm has a market cap of $27.44 million, a price-to-earnings ratio of -0.94 and a beta of 0.23. ContraFect has a 12 month low of $0.27 and a 12 month high of $2.59.
Several large investors have recently bought and sold shares of the company. Oracle Investment Management Inc. raised its holdings in shares of ContraFect by 13.1% in the second quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock valued at $3,242,000 after acquiring an additional 735,450 shares in the last quarter. SG Americas Securities LLC acquired a new position in ContraFect in the second quarter valued at approximately $343,000. Trellus Management Company LLC bought a new position in shares of ContraFect during the second quarter valued at approximately $295,000. Virtu Financial LLC bought a new position in shares of ContraFect during the third quarter valued at approximately $25,000. Finally, Hartwell J M Limited Partnership raised its position in shares of ContraFect by 42.9% during the 3rd quarter. Hartwell J M Limited Partnership now owns 200,000 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 60,000 shares during the period. 31.23% of the stock is owned by institutional investors and hedge funds.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Further Reading: Are we seeing the beginning of a new bubble?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.